The US Supreme Court has overturned two methods patents on drug dose calibration held by biotech company Prometheus Laboratories, reports The Scientist's Sabrina Richards. The company's patents concerned the calibration of synthetic thiopurines, which are used to treat auto-immune diseases like Crohn's disease, Richards says. "Prometheus's methods rely on monitoring the levels of various metabolites in red blood cells," she adds.